EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TIGIT mediates activation-induced cell death of ILC2s during chronic airway allergy

Toshiki Yamada iD, Megumi Tatematsu iD, Shunsuke Takasuga iD, Akane Fuchimukai iD, Kenki Yamagata iD, Shinsuke Seki iD, Keiji Kuba iD, Hideyuki Yoshida iD, Ichiro Taniuchi iD, Günter Bernhardt iD, Kazuko Shibuya iD, Akira Shibuya iD und 2 weitere

Journal of Experimental Medicine · 03.07.2023 · 220 (7)

DOI: 10.1084/jem.20222005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 10.04.2023. Verfasst von Toshiki Yamada und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Akita University Graduate School of Medicine, Akita, Japan. Hauptthemen laut MEDLINE: Hypersensitivity, Immunity, Innate, Receptors, Immunologic. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japanese Society for the Promotion of Science, Takeda Science Foundation, Terumo Life Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While group-2 innate lymphoid cells (ILC2s) are highly proliferative in allergic inflammation, the removal of overactivated ILC2s in allergic diseases has not been investigated. We previously showed that chronic airway allergy induces “exhausted-like” dysfunctional ILC2s expressing T cell immunoreceptor with Ig and ITIM domains (TIGIT). However, the physiological relevance of these cells in chronic allergy remains elusive. To precisely identify and monitor TIGIT+ ILC2s, we generated TIGIT lineage tracer mice. Chronic allergy stably induced TIGIT+ ILC2s, which were highly activated, apoptotic, and were quickly removed from sites of chronic allergy. Transcripts from coding genes were globally suppressed in the cells, possibly due to reduced chromatin accessibility. Cell death in TIGIT+ ILC2s was enhanced by interactions with CD155 expressed on macrophages, whereas genetic ablation of Tigit or blockade by anti-TIGIT antagonistic antibodies promoted ILC2 survival, thereby deteriorating chronic allergic inflammation. Our work demonstrates that TIGIT shifts the fate of ILC2s toward activation-induced cell death, which could present a new therapeutic target for chronic allergies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypersensitivityImmunity, InnateReceptors, ImmunologicAnimalsMiceCell DeathInflammationLymphocytes

Substanzen

T cell Ig and ITIM domain protein, mouseReceptors, Immunologic

Autor:innen und Institutionen

  • Department of Medical Biology, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Pediatric Surgery, Akita University Graduate School of Medicine, Akita, Japan.
  • Experimental Animal Division, Bioscience Education and Research Support Center, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Biochemistry and Metabolic Science, Akita University Graduate School of Medicine, Akita, Japan.
  • YCI Laboratory for Immunological Transcriptomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

ORCID-Profile: Toshiki Yamada, Megumi Tatematsu, Shunsuke Takasuga, Akane Fuchimukai, Kenki Yamagata, Shinsuke Seki, Keiji Kuba, Hideyuki Yoshida, Ichiro Taniuchi, Günter Bernhardt, Kazuko Shibuya, Akira Shibuya, Takechiyo Yamada, Takashi Ebihara

Förderung

  • Japanese Society for the Promotion of Science
  • Takeda Science Foundation
  • Terumo Life Science Foundation
  • Naito Foundation
  • Kyushu University
  • Novartis Foundation
  • Daiichi Sankyo Foundation of Life Science
  • Koyanagi Foundation

Zitieren

APA

Yamada, T., Tatematsu, M., Takasuga, S., Fuchimukai, A., Yamagata, K., Seki, S., Kuba, K., Yoshida, H., Taniuchi, I., Bernhardt, G., Shibuya, K., Shibuya, A., Yamada, T., & Ebihara, T. (2023). TIGIT mediates activation-induced cell death of ILC2s during chronic airway allergy. Journal of Experimental Medicine, 220(7). https://doi.org/10.1084/jem.20222005

Vancouver

Yamada T, Tatematsu M, Takasuga S, Fuchimukai A, Yamagata K, Seki S, et al. TIGIT mediates activation-induced cell death of ILC2s during chronic airway allergy. Journal of Experimental Medicine. 2023;220(7). doi:10.1084/jem.20222005

BibTeX
@article{Yamada2023,
  author = {Yamada, Toshiki and Tatematsu, Megumi and Takasuga, Shunsuke and Fuchimukai, Akane and Yamagata, Kenki and Seki, Shinsuke and Kuba, Keiji and Yoshida, Hideyuki and Taniuchi, Ichiro and Bernhardt, Günter and Shibuya, Kazuko and Shibuya, Akira and Yamada, Takechiyo and Ebihara, Takashi},
  title = {TIGIT mediates activation-induced cell death of ILC2s during chronic airway allergy},
  journal = {Journal of Experimental Medicine},
  year = {2023},
  volume = {220},
  number = {7},
  doi = {10.1084/jem.20222005}
}
Kostenlos starten →